Elanco Animal Health (NYSE:ELAN) Price Target Raised to $26.00 at Morgan Stanley

Elanco Animal Health (NYSE:ELAN) had its price target boosted by Morgan Stanley from $23.00 to $26.00 in a research report report published on Wednesday morning,Benzinga reports. They currently have an equal weight rating on the stock.

ELAN has been the subject of a number of other research reports. Weiss Ratings lowered Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 11th. TD Cowen raised their price target on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, June 18th. Piper Sandler restated an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. JPMorgan Chase & Co. upped their price objective on shares of Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Finally, Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Elanco Animal Health has an average rating of “Moderate Buy” and a consensus price target of $28.73.

Elanco Animal Health Stock Down 0.3%

NYSE:ELAN opened at $25.41 on Wednesday. The company has a market capitalization of $12.69 billion, a price-to-earnings ratio of -50.81, a price-to-earnings-growth ratio of 1.67 and a beta of 1.68. Elanco Animal Health has a one year low of $13.39 and a one year high of $27.72. The stock has a 50-day simple moving average of $23.85 and a 200 day simple moving average of $23.95. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The firm had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.28 billion. During the same quarter in the prior year, the firm posted $0.37 earnings per share. Elanco Animal Health’s revenue for the quarter was up 14.9% compared to the same quarter last year. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Sell-side analysts predict that Elanco Animal Health will post 1.11 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Jeffrey N. Simmons bought 4,971 shares of Elanco Animal Health stock in a transaction dated Friday, May 15th. The stock was acquired at an average cost of $20.09 per share, with a total value of $99,867.39. Following the completion of the acquisition, the chief executive officer directly owned 171,971 shares in the company, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Rajeev A. Modi acquired 4,911 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The stock was purchased at an average cost of $20.35 per share, with a total value of $99,938.85. Following the purchase, the insider directly owned 160,812 shares in the company, valued at approximately $3,272,524.20. This trade represents a 3.15% increase in their position. The disclosure for this purchase is available in the SEC filing. 1.14% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Elanco Animal Health

Hedge funds have recently bought and sold shares of the business. Peak Retirement Planning Inc. acquired a new position in Elanco Animal Health during the fourth quarter worth $2,756,000. Norges Bank bought a new stake in shares of Elanco Animal Health during the 4th quarter worth about $32,415,000. Robeco Institutional Asset Management B.V. acquired a new position in shares of Elanco Animal Health during the 4th quarter valued at about $3,947,000. BNP Paribas Financial Markets raised its stake in shares of Elanco Animal Health by 3,682.0% in the 4th quarter. BNP Paribas Financial Markets now owns 2,252,961 shares of the company’s stock valued at $50,985,000 after acquiring an additional 2,193,391 shares in the last quarter. Finally, OP Asset Management Ltd acquired a new stake in Elanco Animal Health in the 1st quarter worth approximately $8,171,000. 97.48% of the stock is owned by hedge funds and other institutional investors.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.